ObsEva SA to Hold Year End 2019 Financial Results and Business Update Conference Call on March 5, 2020

Geneva, Switzerland and Boston, MA – February 27, 2020 - ObsEva SA OBSV, a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that it will release year end 2019 financial results the morning of Thursday, March 5, 2020.  ObsEva management will host an investment community conference call at 8 a.m. Eastern Time, 2 p.m. Central European Time, on March 5, 2020, to discuss these financial results and provide a corporate update. 

Investors may participate by dialing (844) 419-1772 for U.S. callers or +1 (213) 660-0921 for international callers, and referring to conference ID 2685769.  A webcast of the conference call may be accessed under the "Investors" section of ObsEva's website www.obseva.com.

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol "OBSN". For more information, please visit www.ObsEva.com.

For further information, please contact:

CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact:
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile

Attachment

• Press Release in Pdf